Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cabaletta Bio Inc CABA

Healthcare Biotechnology
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T... see more

Recent & Breaking News (NDAQ:CABA)

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire 5 days ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

GlobeNewswire 11 days ago

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

GlobeNewswire October 27, 2025

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

GlobeNewswire October 14, 2025

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

GlobeNewswire October 9, 2025

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

GlobeNewswire August 27, 2025

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 7, 2025

Cabaletta Bio Announces Pricing of Public Offering of Securities

GlobeNewswire June 11, 2025

Cabaletta Bio Announces Proposed Public Offering of Securities

GlobeNewswire June 11, 2025

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

GlobeNewswire June 11, 2025

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2025

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

GlobeNewswire May 15, 2025

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire March 31, 2025

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle(TM) Platform

Business Wire March 19, 2025

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 26, 2025

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

GlobeNewswire February 18, 2025

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

GlobeNewswire February 18, 2025

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

GlobeNewswire February 11, 2025

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

GlobeNewswire January 29, 2025

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

GlobeNewswire January 13, 2025